International Study Of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) For The Treatment Of Patients With Unresected Stage I/II, Lymph-Node Negative Non-Small Cell Lung Cancer (R3515)
International Study Of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) For The Treatment Of Patients With Unresected Stage I/II, Lymph-Node Negative Non-Small Cell Lung Cancer (R3515)
Trial Category:
Lung
Phase
III
Contact(s)
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE
